Earnings Estimate Revisions for Kyverna Therapeutics, Inc. This company is expected to earn -$3.29 per share for the fiscal year ending December 2024, which represents a year-over-year change of ...

NASDAQ KYTX opened at $3.03 on Thursday. Kyverna Therapeutics has a 1-year low of $2.64 and a 1-year high of $30.60. The business has a 50 day simple moving average of $3.63 and a two-hundred day ...

EMERYVILLE, Calif., March 3, 2025 /PRNewswire/ -- Kyverna Therapeutics, Inc. (Kyverna, Nasdaq: KYTX), a clinical-stage biopharmaceutical company focused on developing cell therapies for patients ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

NEW YORK, NY / ACCESS Newswire / February 4, 2025 / If you suffered a loss on your Kyverna Therapeutics, Inc. (NASDAQ:KYTX) investment and want to learn about a potential recovery under the ...

NEW YORK, NY / ACCESS Newswire / February 2, 2025 / If you suffered a loss on your Kyverna Therapeutics, Inc. (NASDAQ:KYTX) investment and want to learn about a potential recovery under the ...

LOS ANGELES, Jan. 28, 2025 /PRNewswire/ -- Glancy Prongay & Murray LLP announces that investors with losses have opportunity to lead the securities fraud class action lawsuit against Kyverna ...

NEW YORK, Feb. 3, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Kyverna Therapeutics, Inc. (NASDAQ: KYTX). Shareholders who purchased shares of KYTX ...

LOS ANGELES, Feb. 4, 2025 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against Kyverna Therapeutics, Inc. ("Kyverna" or "the Company") (NASDAQ: KYTX) for ...

This feature is currently unavailable; we are sorry for the inconvenience to you. Nasdaq Analyst Research provides analyst research for ratings consensus and a summary of stock price targets ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...